Recent Blog Posts

View Post: Ref Q: APACHE scale Activated Protein C Drotrecogin Alfa
4 Nov 2009 by CYNTHIA YOUNG  
Hi all, Does anyone have any ideas of where to look for the following? I am looking for the latest evidence on APACHE or APACHE II scores to update the Activated Protein C Drotrecogin Alfa (Xigris) protocol. ...
View Blog: MEDLIB-L - http://list.uvm.edu/cgi-bin/wa?A0=MEDLIB-L

---

View Post: Does number needed to treat help with rational decision-making?
17 Nov 2009 by Marya Zilberberg  
Now, let's look at the only therapy on the market that reduces mortality in patients with severe sepsis, drotrecogin alfa (activated). Its NNT is 16. That's right, it takes treating 16 patients to prevent 1 sepsis death. ...
View Blog: Healthcare, etc. - http://evimedgroup.blogspot.com/

---

View Post: Role of Recombinant Human Activated Protein C (Drotrecogin A ...
7 Sep 2007
Drotrecogin alfa (activated), (Xigris®) is a novel drug which has both anti-inflammatory and anticoagulant properties and was approved in 2001 for the reduction in mortality in patients with severe sepsis at a high risk of death. ...
View Blog: Advanced Emergency Nursing Journal - Current... - http://www.aenjournal.com/pt/re/tme/currenttoc.htm

---

View Post: Differential Neuroprotection and Risk for Bleeding From Activated ...
4 Dec 2008 by Wang, Y., Thiyagarajan, M., Chow, N., Singh,...  
Drotrecogin-alfa activated, a hyperanticoagulant form of human recombinant APC, is currently being studied in patients with ischemic stroke. How changes in APC anticoagulant activity influence APC's neuroprotection and risk for bleeding ...
View Blog: Stroke ASAP - http://stroke.ahajournals.org/

---

View Post: the international progress registry of patients with severe sepsis ...
29 Jun 2009 by Richard Beale  
introductionsince the launch of drotrecogin alfa activated (drotaa), institutions and individual countries have published data on its use in clinical practice, based on audit or registry data. these studies were limited in size and ...
View Blog: Critical Care - Latest Articles - http://ccforum.com/

---

View Post: Thrombosis Journal
Full text
Hemostasis and inflammation: two ... ...
View Blog: In this randomized, controlled trial, the administration of recombinant human activated protein C (drotrecogin-alfa) decreased mortality in patients with severe sepsis, a condition characterized by massive activation of the coagulation

---

View Post: Pharma & Biotech Global Week in Review 21 October 2009 from IP ...
21 Oct 2009 by duncan@duncanbucknell.com (Duncan Bucknell)  
Evista (Raloxifene), Xigris (Drotrecogin alfa) – US: Amici briefs in Ariad v Lilly (Holman's Biotech IP Blog) (Patently-O). Fabrazyme (Agalsidase beta) – US: Shelbyzyme files patent infringement suit against Genzyme over manufacture and ...
View Blog: Duncan Bucknell's site updates - http://duncanbucknell.com/ipthinktank.blog

---